... / ... / ... / Researchers / dr. Bart Haagmans

dr. Bart Haagmans

Brief summary of research over the last five years: Bart Haagmans

My research line focusses on the pathogenesis of viral infections and especially those viruses that emerge through zoonotic transmission.  This brings together work performed earlier at the Veterinary faculty in Utrecht and more recent work on human viruses in Rotterdam. Over the last five years we have characterised the genome of Middle East respiratory syndrome (MERS) coronavirus, identified the receptor used by this virus and contributed to the identification of the dromedary camel as the reservoir species. We have tested a vaccine candidate that reduces the transmission of MERS-CoV by vaccinating dromedary camels. These studies led to a more detailed understanding of the biology of this emerging virus and led to novel intervention strategies to contain the outbreak.
In addition, we have characterised the genomes of many other novel viruses and their variants by full genome analysis, including ZIKA virus in the foetus of a woman with miscarriage. Special emphasis was put also on developing protocols for diagnostic work with ebolavirus in western Africa, the existing biosafety laboratories currently operational at the Viroscience Department and the newly built animal biosafety lab. This is compulsory to perform research with these highly pathogenic viruses taking into account appropriate biosafety and biosecurity measures. 

Selection of publications

Miscarriage Associated with Zika Virus Infection.
van der Eijk AA, van Genderen PJ, Verdijk RM, Reusken CB, Mögling R, van Kampen JJ, Widagdo W, Aron GI, GeurtsvanKessel CH, Pas SD, Raj VS, Haagmans BL, Koopmans MP. . N Engl J Med. 2016 Sep 8;375(10):1002-4. doi: 10.1056/NEJMc1605898. (Q1, top10%).

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, Bensaid A, Solanes Foz D, Kuiken T, Baumgärtner W, Segalés J, Sutter G, Osterhaus AD.  Science. 2016 Jan 1;351(6268):77-81. doi: 10.1126/science.aad1283. (Q1, top 10%).

Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014.
Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, Smits SL, Osterhaus AD, Al-Mawlawi N, Al-Romaihi HE, AlHajri MM, El-Sayed AM, Mohran KA, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, El-Maghraby MM, Koopmans MP, Haagmans BL.  Emerg Infect Dis. 2014 Aug;20(8):1339-42. doi: 10.3201/eid2008.140663.

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke GJ, Jonges M, Farag E, Diab A, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, Al Romaihi HE, Al Khal A, Bermingham A, Osterhaus AD, AlHajri MM, Koopmans MP.  Lancet Infect Dis. 2014 Feb;14(2):140-5. doi:10.1016/S1473-3099(13)70690-X. (Q1, top 10%).

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.
Reusken CB*, Haagmans BL*, Müller MA*, Gutierrez C, Godeke GJ, Meyer B, Muth D, Raj VS, Smits- De Vries L, Corman VM, Drexler JF, Smits SL, El Tahir YE, De Sousa R, van Beek J, Nowotny N, van Maanen K, Hidalgo-Hermoso E, Bosch BJ, Rottier P,Osterhaus A, Gortázar-Schmidt C, Drosten C, Koopmans MP.  Lancet Infect Dis. 2013 Oct;13(10):859-66. doi:10.1016/S1473-3099(13)70164-6. (Q1, top 10%).

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL.Nature. 2013 Mar 14;495(7440):251-4. doi:10.1038/nature12005. (Q1, top 10%).

Exacerbated innate host response to SARS-CoV in aged non-human primates.
Smits SL, de Lang A, van den Brand JM, Leijten LM, van IJcken WF, Eijkemans MJ, van Amerongen G, Kuiken T, Andeweg AC, Osterhaus AD, Haagmans BL.  PLoS Pathog. 2010 Feb 5;6(2):e1000756. doi: 10.1371/journal.ppat.1000756. (Q1, top 10%).

Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
van der Eijk AA, Vrolijk JM, Haagmans BL.  N Engl J Med. 2006 Mar 23;354(12):1323-4. (Q1, top 10%).

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD.  Nat Med. 2004 Mar;10(3):290-3. (Q1, top 10%).

Virology: SARS virus infection of cats and ferrets.
119: Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Peiris JS, Lim W, Osterhaus AD.   Nature. 2003 Oct 30;425(6961):915. (Q1, top 10%).